References
- Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62. doi:10.1038/nrclinonc.2017.148
- Yildiz H, Castanares-Zapatero D, d’Abadie P, Bailly S, Yombi JC. Hemophagocytic lymphohistiocytosis in adults: a retrospective study in a Belgian teaching hospital. Int J Gen Med. 2022;15:8111–8120. doi:10.2147/IJGM.S388880
- George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86. doi:10.2147/JBM.S46255
- Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–246. doi:10.1146/annurev-med-041610-134208
- Kayaaslan BU, Asilturk D, Eser F, et al. A case of Hemophagocytic lymphohistiocytosis induced by COVID-19, and review of all cases reported in the literature. J Infect Dev Ctries. 2021;15:1607–1614. doi:10.3855/jidc.14829
- Meazza Prina M, Martini F, Bracchi F, et al. Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report. BMC Infect Dis. 2021;21:811. doi:10.1186/s12879-021-06532-7
- Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417. doi:10.1038/s41467-021-25509-3
- Ali R, Mehannek R, Patel A, et al. Systemic lupus erythematosus with hemophagocytic lymphohistiocytosis: is COVID-19 the inciting factor? Cureus. 2021;13:e19657. doi:10.7759/cureus.19657
- Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30:411–420. doi:10.1016/j.blre.2016.05.001
- Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7:814–822. doi:10.1016/S1473-3099(07)70290-6
- La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133:2465–2477. doi:10.1182/blood.2018894618
- Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–131. doi:10.1002/pbc.21039
- Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66:2613–2620. doi:10.1002/art.38690
- Schnaubelt S, Tihanyi D, Strassl R, et al. Hemophagocytic lymphohistiocytosis in COVID-19: case reports of a stepwise approach. Medicine. 2021;100:e25170. doi:10.1097/MD.0000000000025170
- Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26:263–280. doi:10.1016/j.cytogfr.2014.10.001
- Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474. doi:10.1126/science.abb8925
- Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–2629. doi:10.1172/JCI137244
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5
- Cron RQ, Goyal G, Chatham WW. Cytokine storm syndrome. Annu Rev Med. 2023;74:321–337. doi:10.1146/annurev-med-042921-112837
- Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127:1666–1675. doi:10.1182/blood-2015-12-684399
- Hansen S, Alduaij W, Biggs CM, et al. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: a case series. Eur J Haematol. 2021;106:654–661. doi:10.1111/ejh.13593
- Liu X, Zhu X, Zhou X, et al. Case report: ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS. Front Immunol. 2022;13:1012643. doi:10.3389/fimmu.2022.1012643
- Yildiz H, Bailly S, Van Den Neste E, Yombi JC. Clinical management of relapsed/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag. 2021;17:293–304. doi:10.2147/TCRM.S195538
- Goker Bagca B, Biray Avci C. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine Growth Factor Rev. 2020;54:51–62. doi:10.1016/j.cytogfr.2020.06.013
- Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28:117–23 e1. doi:10.1016/j.chom.2020.05.007